Art. -Nr.: HY-N1198

Strictosamide

Kundenbewertung

Based on 1 Customer Validation

Strictosamide is a compound that can be isolated from Nauclea officinalis. Strictosamide has various activities such as anti-inflammatory, analgesic, anti-Plasmodium, antifungal, and promoting wound healing.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 23141-25-5
Formel: C₂₆H₃₀N₂O₈
Molecular Weight:498.53

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Strictosamide Chemical Structure

CAS. Nr.: 23141-25-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Parasite Isoform-spezifische Produkte anzeigen :

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>80 μM Compound: 21	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31804070]
HepG2	IC₅₀	>80 μM Compound: 21	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31804070]
MCF7	IC₅₀	>80 μM Compound: 21	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 31804070]

In Vitro

Strictosamide (0-200 μM; 24 h) can inhibit the production of NO, TNF-α, and IL-1β, as well as the expression of iNOS in LPS (HY-D1056)-treated RAW 264.7 cells. The mechanism involves the inhibition of the NF-κB and MAPK pathways^[1].
Strictosamide (0.25-2 mg/mL) can inhibit the Mg²⁺-ATPase activity in isolated kidneys^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

LPS (HY-D1056)-treated RAW 264.7 cells
Concentration:

0, 25, 50, 100 and 200 µM
Incubation Time:

24 h
Result:

Markedly decreased the expressions of p-p65, p-IκBα and p-IKKα in NF-κB signaling pathways.
Significantly decreased the phosphorylation of p38, ERK and JNK in MAPK signaling pathways.

In Vivo

Strictosamide (50-200 mg/kg; intraperitoneal injection; single dose) can increase the Na⁺, K⁺-ATPase activity in the mouse brain and inhibit the Mg²⁺-ATPase activity in the mouse kidneys^[2].
Strictosamide (10-40 mg/kg; intravenous injection; twice a day; 3 days) has anti-inflammatory and analgesic effects in multiple mouse models^[3].
Strictosamide (0.5-1.5 mg/kg; topical application; twice a day; 8 days) has a wound-healing-promoting effect in a rat wound model. The mechanism involves the activation of the PI3K/AKT signaling pathway^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR mice, weighing 18-22 g^[3]
Dosage:

10, 20 and 40 mg/kg
Administration:

Intravenous injection; twice a day; 3 days
Result:

Obviously decreased the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mice ear edema (24.7 and 28.1% inhibition, respectively) at 20 and 40 mg/kg.
Significantly inhibited acetic acid (HY-Y0319)-stimulated peritoneal vascular permeability in mice (23.3 and 33.4% inhibition, respectively) at 20 and 40 mg/kg.
Significantly decreased the leukocytes in the mice peritoneal cavity induced by CMC–Na at all the tested doses (46.0, 49.1, and 58.7% inhibition, respectively).
Markedly prolonged the pain latency at 20 and 40 mg/kg and decreased the writhing counts at 40 mg/kg (49.7% inhibition) in acetic acid (HY-Y0319)-induced writhing test in mice. However, it did not obviously improve the pain threshold of mice in hot-plate test.

Animal Model:

Male Sprague Dawley (SD) rats (200-220 g) with skin wound model^[4]
Dosage:

0.5 and 1.5 mg/kg
Administration:

Topical application; twice a day; 8 days
Result:

Promoted wound healing.
Reduced inflammatory infiltration.
Enhanced collagen deposition.
Upregulated the expression of CD31 and PCNA

Chemical Information

CAS. Nr. 23141-25-5
Appearance Solid
Molecular Weight 498.53
Formel C₂₆H₃₀N₂O₈
Color Off-white to yellow
SMILES

O=C1N2CCC3=C(NC4=C3C=CC=C4)[C@]2([H])C[C@]5([H])C1=CO[C@@H](O[C@H]6[C@@H]([C@H]([C@@H]([C@@H](CO)O6)O)O)O)[C@@H]5C=C
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (200.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0059 mL

10.0295 mL

20.0590 mL

5 mM

0.4012 mL

2.0059 mL

4.0118 mL

10 mM

0.2006 mL

1.0029 mL

2.0059 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li D, et al. Anti-inflammatory effect of the six compounds isolated from Nauclea officinalis Pierrc ex Pitard, and molecular mechanism of strictosamide via suppressing the NF-κB and MAPK signaling pathway in LPS-induced RAW 264.7 macrophages. J Ethnopharmacol. 2017 Jan 20;196:66-74. [Content Brief]

[2]. Candeias MF, et al. Effects of strictosamide on mouse brain and kidney Na+, K+-ATPase and Mg2+-ATPase activities. J Ethnopharmacol. 2009 Jan 12;121(1):117-22. [Content Brief]

[3]. Na Li, et al. In vivo anti-inflammatory and analgesic activities of strictosamide from Nauclea officinalis. Pharm Biol. 2014 Nov;52(11):1445-50. [Content Brief]

[4]. Ming GX, et al. Strictosamide promotes wound healing through activation of the PI3K/AKT pathway. Heliyon. 2024 Apr 23;10(9):e30169. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0059 mL	10.0295 mL	20.0590 mL	50.1474 mL
	5 mM	0.4012 mL	2.0059 mL	4.0118 mL	10.0295 mL
	10 mM	0.2006 mL	1.0029 mL	2.0059 mL	5.0147 mL
	15 mM	0.1337 mL	0.6686 mL	1.3373 mL	3.3432 mL
	20 mM	0.1003 mL	0.5015 mL	1.0029 mL	2.5074 mL
	25 mM	0.0802 mL	0.4012 mL	0.8024 mL	2.0059 mL
	30 mM	0.0669 mL	0.3343 mL	0.6686 mL	1.6716 mL
	40 mM	0.0501 mL	0.2507 mL	0.5015 mL	1.2537 mL
	50 mM	0.0401 mL	0.2006 mL	0.4012 mL	1.0029 mL
	60 mM	0.0334 mL	0.1672 mL	0.3343 mL	0.8358 mL
	80 mM	0.0251 mL	0.1254 mL	0.2507 mL	0.6268 mL
	100 mM	0.0201 mL	0.1003 mL	0.2006 mL	0.5015 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Strictosamide

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Antifungal Compound Library

Endoplasmic Reticulum Stress Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Membrane Transporter/Ion Channel Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Alle Parasite Isoform-spezifische Produkte anzeigen

Alle NO Synthase Isoform-spezifische Produkte anzeigen